Stock Track | CareDx Stock Soars on Impressive Q3 2024 Earnings Beat

Stock Track11-06

Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, surged 7.55% on November 6, 2024, following the company's better-than-expected third-quarter 2024 financial results.

For the quarter, CareDx reported revenue of $82.9 million, representing a 23% year-over-year increase and exceeding analyst estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earnings per share loss of $0.14 beat expectations of a $0.43 loss.

Looking ahead, CareDx forecasts revenue growth of 12% per annum on average over the next three years, although this lags the broader US biotechnology industry's forecast of 21% growth. Nevertheless, the company's strong financial performance and positive outlook for continued expansion and profitability improvements appear to have fueled investor confidence, driving the stock's soaring movement on November 6.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167149204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167149204","market":"hk","top_or_hot":-1,"title":"Stock Track | CareDx Stock Soars on Impressive Q3 2024 Earnings Beat","media":"Stock Track","content":"<p>Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, surged 7.55% on November 6, 2024, following the company's better-than-expected third-quarter 2024 financial results.</p>\n\n<p>For the quarter, CareDx reported revenue of $82.9 million, representing a 23% year-over-year increase and exceeding analyst estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earnings per share loss of $0.14 beat expectations of a $0.43 loss.</p>\n\n<p>Looking ahead, CareDx forecasts revenue growth of 12% per annum on average over the next three years, although this lags the broader US biotechnology industry's forecast of 21% growth. Nevertheless, the company's strong financial performance and positive outlook for continued expansion and profitability improvements appear to have fueled investor confidence, driving the stock's soaring movement on November 6.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CareDx Stock Soars on Impressive Q3 2024 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CareDx Stock Soars on Impressive Q3 2024 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 22:33 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, surged 7.55% on November 6, 2024, following the company's better-than-expected third-...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDNA","symbol_name":"CareDx","start_time":0,"source_url":"","article_id":"1167149204","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167149204","pubTimestamp":1730903624,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CareDx , a leading precision medicine company specializing in transplant diagnostics, surged 7.55% on November 6, 2024, following the company's better-than-expected third-quarter 2024 financial results.For the quarter, CareDx reported revenue of $82.9 million, representing a 23% year-over-year increase and exceeding analyst estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earnings per share loss of $0.14 beat expecta","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDNA":"CareDx"},"translate_title":"股票跟踪CareDx股票因2024年第三季度盈利令人印象深刻而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1},"content_text":"Shares of CareDx (NASDAQ: CDNA), a leading precision medicine company specializing in transplant diagnostics, surged 7.55% on November 6, 2024, following the company's better-than-expected third-quarter 2024 financial results.\nFor the quarter, CareDx reported revenue of $82.9 million, representing a 23% year-over-year increase and exceeding analyst estimates by 2.7%. The company's net loss narrowed significantly by 69% compared to the same period last year, and its earnings per share loss of $0.14 beat expectations of a $0.43 loss.\nLooking ahead, CareDx forecasts revenue growth of 12% per annum on average over the next three years, although this lags the broader US biotechnology industry's forecast of 21% growth. Nevertheless, the company's strong financial performance and positive outlook for continued expansion and profitability improvements appear to have fueled investor confidence, driving the stock's soaring movement on November 6.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167149204"}